Ad
related to: new kidney cancer drugs
Search results
Results from the WOW.Com Content Network
Researchers say a new study of kidney cancer offers hope for treating the disease using existing drugs. The study of the cancer at a single-cell level has discovered a potential drug target to ...
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006.
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
This is an accepted version of this page This is the latest accepted revision, reviewed on 18 January 2025. Medical condition Kidney cancer Other names Renal cancer Micrograph showing the most common type of kidney cancer (clear cell renal cell carcinoma). H&E stain. Specialty Oncology nephrology Urology Symptoms Blood in the urine, lump in the abdomen, back pain Usual onset After the age of ...
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
AVEO Pharmaceuticals' announced yesterday that the Food and Drug Administration rejected its kidney cancer drug tivozanib. No surprise there. The briefing documents for the advisory panel meeting ...
Ad
related to: new kidney cancer drugs